Nichols & Pratt Advisers’s Medtronic MDT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$11M Sell
141,131
-15,285
-10% -$1.23M 0.67% 32
2026
Q1
$13.6M Sell
156,416
-1,732
-1% -$166K 0.87% 31
2025
Q4
$15.2M Buy
158,148
+270
+0.2% +$26.2K 0.95% 30
2025
Q3
$15M Buy
157,878
+109
+0.1% +$10K 0.95% 28
2025
Q2
$13.8M Buy
157,769
+1,383
+0.9% +$117K 0.92% 30
2025
Q1
$14M Sell
156,386
-4,776
-3% -$427K 0.96% 30
2024
Q4
$12.9M Buy
161,162
+2,765
+2% +$239K 0.86% 31
2024
Q3
$14.3M Sell
158,397
-6,890
-4% -$580K 0.92% 30
2024
Q2
$13M Buy
165,287
+25
+0% +$2.05K 0.88% 30
2024
Q1
$14.4M Sell
165,262
-1,349
-0.8% -$115K 0.97% 30
2023
Q4
$13.7M Sell
166,611
-240
-0.1% -$18.3K 0.98% 29
2023
Q3
$13M Buy
166,851
+205
+0.1% +$17.2K 0.99% 31
2023
Q2
$14.7M Buy
166,646
+21,950
+15% +$1.89M 1.07% 30
2023
Q1
$11.6M Buy
144,696
+8,420
+6% +$686K 0.89% 30
2022
Q4
$10.6M Buy
136,276
+1,814
+1% +$147K 0.85% 32
2022
Q3
$10.9M Buy
134,462
+130
+0.1% +$11.7K 0.96% 30
2022
Q2
$12.1M Buy
134,332
+855
+0.6% +$86.6K 0.99% 30
2022
Q1
$14.8M Buy
133,477
+2,175
+2% +$230K 1.07% 29
2021
Q4
$13.6M Buy
131,302
+1,060
+0.8% +$123K 0.94% 34
2021
Q3
$16.5M Buy
130,242
+250
+0.2% +$32.4K 1.25% 28
2021
Q2
$16.1M Buy
129,992
+1,300
+1% +$163K 1.22% 29
2021
Q1
$15.2M Buy
128,692
+1,120
+0.9% +$131K 1.18% 29
2020
Q4
$14.9M Buy
127,572
+3,515
+3% +$387K 1.18% 32
2020
Q3
$12.9M Buy
124,057
+8,347
+7% +$838K 1.11% 31
2020
Q2
$10.6M Buy
115,710
+1,360
+1% +$130K 0.95% 37
2020
Q1
$10.2M Buy
114,350
+2,075
+2% +$221K 1.02% 36
2019
Q4
$12.7M Sell
112,275
-7,264
-6% -$797K 1.05% 35
2019
Q3
$13M Buy
119,539
+1,280
+1% +$134K 1.06% 34
2019
Q2
$11.5M Buy
118,259
+4,157
+4% +$380K 0.95% 35
2019
Q1
$10.4M Buy
114,102
+6,620
+6% +$593K 0.87% 38
2018
Q4
$9.71M Sell
107,482
-890
-0.8% -$83.2K 0.91% 37
2018
Q3
$10.7M Buy
108,372
+1,811
+2% +$167K 0.89% 40
2018
Q2
$9.12M Buy
106,561
+906
+0.9% +$75.7K 0.82% 40
2018
Q1
$8.41M Buy
105,655
+5,835
+6% +$481K 0.77% 40
2017
Q4
$8.09M Buy
99,820
+129
+0.1% +$10.3K 0.7% 41
2017
Q3
$7.76M Buy
99,691
+3,615
+4% +$300K 0.69% 41
2017
Q2
$8.53M Buy
96,076
+315
+0.3% +$26.6K 0.78% 40
2017
Q1
$7.72M Sell
95,761
-40
-0% -$3.13K 0.71% 40
2016
Q4
$6.81M Buy
95,801
+135
+0.1% +$10.6K 0.64% 40
2016
Q3
$8.27M Buy
95,666
+225
+0.2% +$19.6K 0.76% 39
2016
Q2
$8.29M Buy
95,441
+280
+0.3% +$22.6K 0.75% 40
2016
Q1
$7.14M Buy
95,161
+210
+0.2% +$15.8K 0.66% 43
2015
Q4
$7.3M Sell
94,951
-1,774
-2% -$134K 0.7% 41
2015
Q3
$6.5M Sell
96,725
-549
-0.6% -$40.4K 0.65% 44
2015
Q2
$7.21M Buy
97,274
+3,860
+4% +$295K 0.67% 41
2015
Q1
$7.29M Buy
93,414
+1,145
+1% +$86.8K 0.66% 38
2014
Q4
$6.66M Buy
92,269
+2,245
+2% +$156K 0.59% 41
2014
Q3
$5.59M Sell
90,024
-6,550
-7% -$416K 0.5% 44
2014
Q2
$6.16M Sell
96,574
-3,041
-3% -$185K 0.53% 42
2014
Q1
$6.13M Sell
99,615
-1,650
-2% -$96.1K 0.56% 43
2013
Q4
$5.81M Buy
101,265
+1,025
+1% +$58.1K 0.55% 41
2013
Q3
$5.34M Buy
100,240
+65
+0.1% +$3.5K 0.54% 42
2013
Q2
$5.17M Buy
+100,175
New +$4.95M 0.54% 42

Other funds holding MDT

Nichols & Pratt Advisers's MDT Position: Q2 2026 in Review

Nichols & Pratt Advisers reduced its Medtronic (MDT) stake by 9.8% in Q2 2026, selling an estimated $1.23M and leaving 141,131 shares worth $11M. The position accounts for 0.67% of the portfolio, ranked #32.

Nichols & Pratt Advisers first reported a position in MDT in Q2 2013 and has held it in 53 quarters since. The position peaked at $16.5M in Q3 2021. 2,128 funds tracked by Wall St. Rank hold MDT as of Q2 2026.

  • Nichols & Pratt Advisers held 141,131 shares of Medtronic worth $11M as of Q2 2026.
  • Nichols & Pratt Advisers sold 15,285 Medtronic shares in Q2 2026, an estimated $1.23M.
  • Medtronic made up 0.67% of Nichols & Pratt Advisers's portfolio in Q2 2026, its #32 holding.
  • Nichols & Pratt Advisers first reported a position in Medtronic in Q2 2013 and has held it in 53 quarters since.
  • Nichols & Pratt Advisers's Medtronic position peaked at $16.5M in Q3 2021.
  • 2,128 funds tracked by Wall St. Rank held Medtronic as of Q2 2026.

Based on Nichols & Pratt Advisers's 13F filing for Q2 2026, filed 5 Aug 2026.